Valiant Laboratories

Valiant Laboratories Capital Intensity

The Capital Intensity Ratio of Valiant Laboratories (VALIANTLAB.NS) as of Nov 4, 2026 is 195.39 %. In the previous year, Capital Intensity Ratio was 288.77 % — a change of -32.34% (lower).

Capital Intensity

195.39 %

YoY

-32.34%

Last updated:

Capital Intensity Ratio of Valiant Laboratories is 2026 195.39 % . Capital Intensity Ratio of Valiant Laboratories was 2025 288.77 % . It decreases by -32.34% lower compared to the previous year.

The Valiant Laboratories Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2021
58.30 INR
Jan 1, 2022
62.37 INR
Jan 1, 2023
63.78 INR
Jan 1, 2024
188.23 INR
Jan 1, 2025
288.77 INR
Jan 1, 2026
195.39 INR
The Valiant Laboratories Capital Intensity history
YEARCapital IntensityYoY
195.39 %-32.34%
288.77 %+53.41%
188.23 %+195.13%
63.78 %+2.27%
62.37 %+6.98%
58.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valiant Laboratories Stock analysis

What does Valiant Laboratories do? Valiant Laboratories Ltd manufactures paracetamol API/bulk drug for pharmaceutical applications, targeting medical conditions such as headache, muscle ache, arthritis, back ache, toothache, cold, and fever. The company operates a single manufacturing facility at Tarapur industrial estate, approximately 150 km from Nhava Sheva Port (JNPT), producing specialty chemicals and pharma intermediates for domestic and international markets. Its subsidiary, VALIANT ADVANCED SCIENCES PRIVATE LIMITED, supports the company's operations in the pharmaceutical sector. The firm's primary revenue comes from selling paracetamol API and specialty chemicals to pharmaceutical companies and distributors globally. Manufacturing focuses on high-demand applications like pain relief and fever treatment, with products distributed across India and abroad. The company leverages its Tarapur facility's proximity to Nhava Sheva Port for efficient export logistics. Valiant Laboratories Ltd serves the pharmaceutical industry by supplying essential active ingredients, particularly paracetamol, which is widely used in over-the-counter medications. The company's manufacturing capabilities for specialty chemicals and pharma intermediates cater to both domestic and international clients seeking reliable API sources. Its single-location production model ensures focused resource allocation for consistent output quality. Valiant Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valiant Laboratories stock

Capital Intensity Ratio of Valiant Laboratories is 195.39 % in 2026.

Capital Intensity Ratio of Valiant Laboratories changed from 288.77 % to 195.39 %, representing a -32.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Valiant Laboratories since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Valiant Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Valiant Laboratories

All Key Metrics — Valiant Laboratories